A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Overfishing of fish species targeted for their fish bladders has led to fish stock collapse. The first major population decline from the swim bladder trade was of the Chinese bahaba or giant yellow croaker Bahaba taipingensis of the China Seas. While Chinese bahaba fishing was banned for domestic trade in 1989 after the classification of the fish as Class II under the Wildlife Protection Law of the People's Republic of China, the Chinese bahaba population continued to decline and was added to the IUCN Red List in 2009. The totoaba began to be targeted for its perceived similarity to the Chinese bahaba by the 1920s, and increased in scope until it was categorized as a vulnerable species. On Lake Victoria, there is increased usage of illegal monofilament nets and targeting of undersized fish, impacting the Nile perch population. Kenya, Uganda and Tanzania have beach patrols and fishing regulations to regulate the fish maw trade.
=== Misinterpretation of "DTO" === The abbreviation "DTO," traditionally used to refer to Deodorized Tincture of Opium, is sometimes also erroneously employed to abbreviate "diluted tincture of opium." Diluted tincture of opium, also known as Camphorated Tincture of Opium (Paregoric) is a 1:25 mixture of opium tincture to water prescribed to treat withdrawal symptoms in newborns whose mothers were using opioids while pregnant. The United States Pharmacopeia and FDA recommend that practitioners refrain from using DTO in prescriptions, given this potential for confusion. In cases where pharmacists have misinterpreted DTO, and given "deodorized tincture of opium" when "diluted tincture of opium" was meant, infants have received a massive 25-fold overdose of morphine, sometimes resulting in fatalities.
=== Sexual abuse claims === Duterte has claimed he was sexually abused by a priest when he was a minor. After he was challenged by the Catholic Bishops' Conference of the Philippines (CBCP) and AdDU officials to name the priest and file a case against him, Duterte then revealed the priest's name as Mark Falvey (died 1975). The Jesuits of the Society of Jesus in the Philippines confirmed that according to press reports in the United States, in May 2007, the Society of Jesus agreed to a tentative payout of US$16 million to settle claims that Falvey sexually abused at least nine children in Los Angeles from 1959 to 1975. Accusations against Falvey began in 2002, although he was never charged with a crime. In May 2008, the Diocese of Sacramento paid a $100,000-settlement to a person allegedly raped and molested by Mark's brother, Arthur Falvey. However, it was not clearly indicated in the report if Mark Falvey was assigned at the Jesuit-run Ateneo de Davao. When asked why he did not complain when the abuse supposedly happened, Duterte claimed that he was too young to complain about the priest's abuse and was intimidated by authorities at that time. He also stated that he never disclosed the abuse even after he was expelled and moved to a different high school, not even to his family.
Sources: en.wikipedia.org
Cysteine-rich proteins (CRP, cysteine-rich peptide or disulphide-rich peptide) are small proteins that contain a large number of cysteines. These cysteines either cross-link to form disulphide bonds, or bind metal ions by chelation, stabilising the protein's tertiary structure. CRPs include a highly conserved secretion peptide signal at the N-terminus and a cysteine-rich region at the C-terminus.
Fibrodysplasia ossificans progressiva (; abbr. FOP), also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease. Fibrous connective tissue such as muscle, tendons, and ligaments ossify into bone tissue. The condition ultimately immobilises sufferers, as new bone replaces musculature and fuses with the existing skeleton. This has earned FOP the nickname "stone man disease". FOP is caused by a mutation of the gene ACVR1, affecting the body's repair mechanism. Fibrous tissue, including muscle, tendons, and ligaments ossify, either spontaneously or when damaged by trauma. In many cases, otherwise minor injuries can cause joints to permanently fuse as new bone forms, replacing the damaged muscle tissue. This new bone formation (known as "heterotopic ossification") eventually forms a secondary skeleton progressively restricting the patient's ability to move. Circumstantial evidence suggests that the disease can cause joint degradation separate from its characteristic bone growth. It is a severe, debilitating disorder. Bone formed as a result of ossification is identical to "normal" bone, but in improper locations. The rate of ossified bone growth varies by patient. It is the only known medical condition in which tissue of one organ system changes into that of another. Surgical removal of ossified bone causes the body to "repair" the affected area with additional bone. FOP has no current known cure. However, there are intermittent treatments such as anti-inflammatory drugs.
== External links == Current and future therapeutic strategies for metastatic ACC (AdrenoCortical Carcinomas) (Video with Univ.-Prof. Dr. med. Martin Fassnacht, University Clinic, Wuerzburg) Application of mitotane therapy in ACC, AdrenoCortical Carcinomas (Video with Prof. Massimo Terzolo, University of Turin) European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors (European Journal of Endocrinology, Volume 189, Issue 1, July 2023, Pages G1–G42) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors (European Journal of Endocrinology. 2018 Oct 1;179(4):G1-G46.
==== Group B – Acetonides (and related substances) ==== Amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, and Deflazacort (O-isopropylidene derivative)
Sources: en.wikipedia.org
=== February === 1 February – A Statutory Instrument paving the way for the Northern Ireland Executive to be re-established is passed by the House of Commons. Conservative MP Mike Freer announces he is standing down from Parliament at the next election following death threats and an arson attack on his constituency office. Downing Street describes the situation as "an attack on democracy". Addressing a meeting of business leaders, Shadow Chancellor Rachel Reeves says that Labour would not increase corporation tax if elected, but may cut it to boost "competitiveness". Penny Mordaunt, the Leader of the House of Commons, has argued plans to expand the Senedd from 60 to 96 MSs would be the equivalent of expanding the House of Commons from 650 to 2,000 MPs. MP Christina Rees is readmitted to the Labour Party but announces her retirement at the next general election. 2 February – Senior Labour MP Darren Jones confirms that the party has ditched its commitment to spend £28bn a year on green investment schemes if it wins the next general election. 3 February – 2024 Northern Ireland Executive Formation: The Northern Ireland Assembly meets to elect a new Speaker. Edwin Poots, a former leader of the DUP, is chosen to be the Assembly's 7th Speaker. The Northern Ireland Executive is restored after the DUP ends its two year boycott; Sinn Féin's Michelle O'Neill is nominated as First Minister, becoming the first nationalist politician to hold the post, while the DUP's Emma Little-Pengelly is appointed deputy. SDLP MLA Matthew O'Toole is nominated as Leader of the Opposition.
The first step in the NADP-ME type C4 pathway is the conversion of pyruvate (Pyr) to phosphoenolpyruvate (PEP), by the enzyme Pyruvate phosphate dikinase (PPDK). This reaction requires inorganic phosphate and ATP plus pyruvate, producing PEP, AMP, and inorganic pyrophosphate (PPi). The next step is the carboxylation of PEP by the PEP carboxylase enzyme (PEPC) producing oxaloacetate. Both of these steps occur in the mesophyll cells: pyruvate + Pi + ATP → PEP + AMP + PPi PEP + CO2 → oxaloacetate PEPC has a low KM for HCO−3 — and, hence, high affinity, and is not confounded by O2 thus it will work even at low concentrations of CO2. The product is usually converted to malate (M), which diffuses to the bundle-sheath cells surrounding a nearby vein. Here, it is decarboxylated by the NADP-malic enzyme (NADP-ME) to produce CO2 and pyruvate. The CO2 is fixed by RuBisCo to produce phosphoglycerate (PGA) while the pyruvate is transported back to the mesophyll cell, together with about half of the phosphoglycerate (PGA). This PGA is chemically reduced in the mesophyll and diffuses back to the bundle sheath where it enters the conversion phase of the Calvin cycle. For each CO2 molecule exported to the bundle sheath the malate shuttle transfers two electrons, and therefore reduces the demand of reducing power in the bundle sheath.
Later 1987 experiments on the longer-lived isotope 260Lr confirmed lawrencium's trivalency and that it eluted in roughly the same place as erbium, and found that lawrencium's ionic radius was 88.6±0.3 pm, larger than would be expected from simple extrapolation from periodic trends. Later 1988 experiments with more lawrencium atoms refined this to 88.1±0.1 pm and calculated an enthalpy of hydration value of −3685±13 kJ/mol. It was also found that the actinide contraction at the end of the actinides was larger than the analogous lanthanide contraction, with the exception of the last actinide, lawrencium: the cause was speculated to be relativistic effects. It has been speculated that the 7s electrons are relativistically stabilized, so that in reducing conditions, only the 7p1/2 electron would be ionized, leading to the monovalent Lr+ ion. However, all experiments to reduce Lr3+ to Lr2+ or Lr+ in aqueous solution were unsuccessful, similarly to lutetium. On the basis of this, the standard electrode potential of the E°(Lr3+ → Lr+) couple was calculated to be less than −1.56 V, indicating that the existence of Lr+ ions in aqueous solution was unlikely. The upper limit for the E°(Lr3+ → Lr2+) couple was predicted to be −0.44 V: the values for E°(Lr3+ → Lr) and E°(Lr4+ → Lr3+) are predicted to be −2.06 V and +7.9 V. The stability of the group oxidation state in the 6d transition series decreases as RfIV > DbV > SgVI, and lawrencium continues the trend with LrIII being more stable than RfIV.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.